Achieve Life Sciences +47% on results of smoking cessation aid studies

Jun. 26, 2018 8:36 AM ETAchieve Life Sciences, Inc. (ACHV)By: Carl Surran, SA News Editor
  • Achieve Life Sciences (NASDAQ:ACHV) +47.3% premarket after announcing positive results from a series of drug metabolism, drug-drug interaction and transporter studies with cytisine, its product candidate being evaluated as an aid to smoking cessation.
  • ACHV says the study showed that cytisine has no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters.
  • The findings suggest cytisine may be administered with other medications without the need to modify the dose of the co-administered drug, the company says.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.